Baseline patient characteristics
| Characteristic . | No. (%) . |
|---|---|
| Total patients in analysis | 1514 |
| Age, y | |
| Mean | 45 |
| Standard deviation | 12 |
| Sex | |
| Male | 769 (51) |
| Female | 745 (49) |
| Race | |
| White | 1311 (87) |
| Black | 155 (10) |
| Other | 48 (3) |
| Disease category | |
| Hematologic malignancy | 1291 (85) |
| Solid tumor | 223 (15) |
| Diagnosis | |
| Hematologic malignancies | |
| Non-Hodgkin lymphoma | 508 (34) |
| Acute myeloid leukemia | 219 (14) |
| Multiple myeloma | 147 (10) |
| Hodgkin disease | 138 (9) |
| Chronic myeloid leukemia | 114 (8) |
| Acute lymphocytic leukemia | 59 (4) |
| Myelodysplastic syndrome | 47 (3) |
| Chronic lymphocytic leukemia | 37 (2) |
| Aplastic anemia | 20 (1) |
| Other | 2 (<1) |
| Solid tumors | |
| Breast | 191 (13) |
| Ovarian | 23 (2) |
| Other | 9 (<1) |
| Type of transplantation | |
| Autologous | 928 (61) |
| Allogeneic | 586 (39) |
| Conditioning regimen | |
| Busulfan-cyclophosphamide | 830 (55) |
| Cyclophosphamide-total body irradiation | 397 (26) |
| Cyclophosphamide-thiotepa | 191 (13) |
| Carboplatin-based | 32 (2) |
| Cyclophosphamide | 16 (1) |
| Melphalan | 9 (1) |
| Other | 5 (<1) |
| Unknown | 34 (2) |
| Duration of hospitalization, d | |
| Median | 26 |
| IQR 25 to 75 | 21-36 |
| Vital status at discharge | |
| Alive | 1384 (91) |
| Dead | 130 (9) |
| Overall survival after transplantation, d | |
| Median | 269 |
| IQR | 86-826 |
| Complications of transplantation | |
| Graft-versus-host disease | 300 (20) |
| Veno-occlusive disease | 99 (7) |
| Cytomegalovirus | 86 (6) |
| Immune modulators | |
| Cyclosporine | 673 (44) |
| Corticosteroids | 293 (19) |
| Characteristic . | No. (%) . |
|---|---|
| Total patients in analysis | 1514 |
| Age, y | |
| Mean | 45 |
| Standard deviation | 12 |
| Sex | |
| Male | 769 (51) |
| Female | 745 (49) |
| Race | |
| White | 1311 (87) |
| Black | 155 (10) |
| Other | 48 (3) |
| Disease category | |
| Hematologic malignancy | 1291 (85) |
| Solid tumor | 223 (15) |
| Diagnosis | |
| Hematologic malignancies | |
| Non-Hodgkin lymphoma | 508 (34) |
| Acute myeloid leukemia | 219 (14) |
| Multiple myeloma | 147 (10) |
| Hodgkin disease | 138 (9) |
| Chronic myeloid leukemia | 114 (8) |
| Acute lymphocytic leukemia | 59 (4) |
| Myelodysplastic syndrome | 47 (3) |
| Chronic lymphocytic leukemia | 37 (2) |
| Aplastic anemia | 20 (1) |
| Other | 2 (<1) |
| Solid tumors | |
| Breast | 191 (13) |
| Ovarian | 23 (2) |
| Other | 9 (<1) |
| Type of transplantation | |
| Autologous | 928 (61) |
| Allogeneic | 586 (39) |
| Conditioning regimen | |
| Busulfan-cyclophosphamide | 830 (55) |
| Cyclophosphamide-total body irradiation | 397 (26) |
| Cyclophosphamide-thiotepa | 191 (13) |
| Carboplatin-based | 32 (2) |
| Cyclophosphamide | 16 (1) |
| Melphalan | 9 (1) |
| Other | 5 (<1) |
| Unknown | 34 (2) |
| Duration of hospitalization, d | |
| Median | 26 |
| IQR 25 to 75 | 21-36 |
| Vital status at discharge | |
| Alive | 1384 (91) |
| Dead | 130 (9) |
| Overall survival after transplantation, d | |
| Median | 269 |
| IQR | 86-826 |
| Complications of transplantation | |
| Graft-versus-host disease | 300 (20) |
| Veno-occlusive disease | 99 (7) |
| Cytomegalovirus | 86 (6) |
| Immune modulators | |
| Cyclosporine | 673 (44) |
| Corticosteroids | 293 (19) |
IQR indicates interquartile range.